{"filing":{"accession_number":"0001628280-26-046143","cik":"0001411685","ticker":"VTGN","company_name":"Vistagen Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"vtgn-20260630.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026046143/vtgn-20260630.htm"},"events":[{"id":14867,"run_id":13252,"accession_number":"0001628280-26-046143","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Vistagen announced topline results from the PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder, which failed to achieve its primary endpoint (p=0.427) in the overall population, though post-hoc analysis showed nominal statistical significance in a severe subpopulation. This material clinical development setback for the company's most advanced product candidate was disclosed via press release and conference call.","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12436,"accession_number":"0001628280-26-046143","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vistagen announced topline and post-hoc data from the PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder. The primary endpoint was not achieved in the overall trial population (p=0.427), though a post-hoc analysis showed nominal statistical significance in a severe subpopulation. This is a material clinical development milestone for the company's most advanced product candidate, disclosed via press release and conference call. While not a traditional earnings release (which reports financial results), this clinical trial outcome is a significant operational and strategic event affecting the company's development pathway and investor assessment of its pipeline value.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:29:41.862979+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12437,"accession_number":"0001628280-26-046143","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vistagen announced that its PALISADE-4 Phase 3 trial of fasedienol failed to achieve its primary endpoint (p=0.427), though a post-hoc analysis showed nominal significance in a severe subpopulation. This is a material clinical trial failure for the company's most advanced product candidate, affecting the development pathway and regulatory strategy. While not a traditional earnings release or restatement, the failure of a pivotal Phase 3 trial is a significant operational/clinical setback that would materially affect investor assessment of the company's prospects and pipeline value.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:29:41.862979+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12436,"accession_number":"0001628280-26-046143","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vistagen announced topline and post-hoc data from the PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder. The primary endpoint was not achieved in the overall trial population (p=0.427), though a post-hoc analysis showed nominal statistical significance in a severe subpopulation. This is a material clinical development milestone for the company's most advanced product candidate, disclosed via press release and conference call. While not a traditional earnings release (which reports financial results), this clinical trial outcome is a significant operational and strategic event affecting the company's development pathway and investor assessment of its pipeline value.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:29:41.862979+00:00","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-06-30"},{"id":12437,"accession_number":"0001628280-26-046143","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vistagen announced that its PALISADE-4 Phase 3 trial of fasedienol failed to achieve its primary endpoint (p=0.427), though a post-hoc analysis showed nominal significance in a severe subpopulation. This is a material clinical trial failure for the company's most advanced product candidate, affecting the development pathway and regulatory strategy. While not a traditional earnings release or restatement, the failure of a pivotal Phase 3 trial is a significant operational/clinical setback that would materially affect investor assessment of the company's prospects and pipeline value.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T12:29:41.862979+00:00","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-06-30"}]}